Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40620-022-01289-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lesson for the clinical nephrologist: thrombotic microangiopathy associated with metastatic prostate cancer.
J Nephrol
December 2024
Division of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
Complement-mediated hemolytic uremic syndrome associated with postpartum hemorrhage: case series and systematic review of individual participant data.
Res Pract Thromb Haemost
November 2024
Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
Background: Postpartum hemorrhage is considered a risk factor for pregnancy-associated complement-mediated hemolytic uremic syndrome (CM-HUS; previously known as atypical hemolytic uremic syndrome) but has not been systematically studied.
Objectives: To systematically examine the role of postpartum hemorrhage in precipitating CM-HUS and to describe the characteristics of postpartum hemorrhage-associated CM-HUS, its prognosis and recommended management.
Methods: A systematic review of individual participant data from case series and reports in addition to a case series from our institution.
Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.
J Manag Care Spec Pharm
December 2024
Health Economics and Value Assessment, Sanofi, Boston, MA.
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration for iTTP, to be given in combination with plasma exchange therapy (PEX) and immunosuppression (IS). The National Institute for Health and Care Excellence's independent appraisal committee assessed the cost-effectiveness of caplacizumab and concluded that the addition of caplacizumab to PEX+IS is cost-effective under a patient access scheme in the United Kingdom.
View Article and Find Full Text PDFInduction of Plasmalemmal vesicle-associated protein exacerbates glomerular endothelial injury in thrombotic microangiopathy.
Am J Physiol Renal Physiol
December 2024
Division of Nephrology, Department of Medicine, Stony Brook University, , Stony Brook, NY.
Glomerular endothelial cell (GEnC) injury is a common feature across the wide spectrum of glomerular diseases. We recently reported that the endothelial-specific knockout of increases the susceptibility to GEnC injury and subsequent development of subacute thrombotic microangiopathy (TMA). However, the mechanism(s) mediating GEnCs response to injury in TMA are poorly understood.
View Article and Find Full Text PDFModified G-CSF/ATG-Based Haploidentical Transplantation Protocol in Pediatric Primary Hemophagocytic Lymphohistiocytosis: A Long-Term Follow-Up Single-Center Experience.
Pediatr Blood Cancer
December 2024
Department of Hematology and Oncology, Beijing Jingdu Children's Hospital, Beijing, China.
Background: Primary hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome caused by immune dysregulation. Hematopoietic stem cell transplantation (HSCT) represents the only option for long-term cure for primary HLH. However, only around 25% of patients have a fully HLA-matched donor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!